Sun
Pharmaceutical Industries Ltd has posted a net profit after tax and minority
interest ofRs.8202.10
mn for the quarter endedMarch
31, 2012where as the same was atRs.4427.50 mn for the
quarter endedMarch
31, 2011.

T

otal
Income isRs.25480.50
mn for the quarter endedMarch
31, 2012where as the same was atRs.15950.80
mn for the quarter endedMarch
31, 2011.

The Group
has posted a
net profit after tax and minority interest ofRs.25872.50 mn for the year endedMarch
31, 2012where as the same was atRs.18160.60
mn for the year endedMarch 31, 2011.

Total Income isRs.84296.90
mn for the year endedMarch
31, 2012where as the same was atRs.60857.50
mn for the year endedMarch
31, 2011.

Mr.Makov is the Chairman of Sun Pharma
Industries Ltd

Sun Pharmaceutical
Industries Ltd has announced that the Board of Directors of the Company at its
meeting held onMay
29, 2012,
has appointed Israel Makov. a resident ofIsrael,
as an additional Director on the Board of Directors of the Company.

Further the Company has informed that, Dilip
Shanghvi has stepped down from the Chairmanship of the Company while continuing
to remain the Managing Director of the Company and Israel Makov has been
appointed as the Chairman of the Company at meeting of the Board of Directors
of the Company held onMay
29, 2012.

Speaking on the induction,Dilip
Shanghvi, Managing Director of Sun Pharmasaid
“I welcome Makov on behalf of
the entire Board and the larger Sun Pharma team. He is an exceptional
leader with deep knowledge and experience in globalizing businesses
successfully. As Sun Pharma continues to rapidly expand its presence worldwide,
I am sure that we will benefit immensely from his experience.”

On
his appointment,
Makov said, “I am happy to accept the position of Chairman of the Board.
Sun Pharma is an exciting company poised for substantial global expansion and I
look forward to working together with Dilip and his team in realizing their
visionary goals.”

GVK EMRI
108 Neonatal Ambulances in Madhya Pradesh

Government
ofMadhya
Pradesh and GVK Emergency Management and Research Institute(GVK
EMRI) started the new service of Neonatal Ambulances in Madhya Pradesh.
Neonatal Ambulances will provide extra care to the new born babies and the
infection prone patients.

In
Neonatal Ambulance, the neonate’s cabin is specially created to make it
sterile. It also has collapsible bed, attendant sheet, medical storage cabinet,
and central oxygen line system. The ambulance is also equipped with the
following:-

Incubator
Unit

Pulse
Oxy meter with neonatal probe.

UPS- for incubator running

Separate
oxygen support system

Baby
Resuscitation Kit - Ambu Bag Case

Overhead
Ceiling Radiant Warmer

And
other equipments

The
launch of the neonatal ambulances was done on29th
May, 2012. The chief guest for the occasion was Dr. Narottam
Mishra, Honorable Minister Public Health and Family Welfare, Govt of Madhya Pradesh.
The launch function was held at the GVK EMRI 108 office at Idgah Hills.

Speaking
on this occasion Dr, Narottam Mishra, Health Minister, said, “I congratulate
GVK EMRI on behalf of department. This is one more addition in the
services being provided by the organization. This service will provide the
transportation service to the infants which otherwise was quite difficult.”

Dr.
Pankaj Shukla , CHMO ,Bhopal said, “GVK EMRI is already providing
emergency services to the victims, we are offering them all help we can from
available resources with us. And we hope they will provide these services to
the kids and the patients in the future as well.”

Subodh
Satyawadi , CEO, GVK EMRI, said “Neonatal ambulance is the demand of the
time. Transportation of sick newborn babies to higher facilities would increase
their survival chances. This is a new initiative from our side for the new
born.”

The
launch function was attended by the team of GVK EMRI and the people from the
health and family welfare department. All of them were very glad as now they
have one more feather in their cap.

The
US Food and Drug Administration (US FDA) has issued a final rule on sterility
testing onMay
3, 2012, that amends the requirements for most
licensed biological products and aims to provide manufacturers with the
flexibility, as appropriate, to keep pace with technological and scientific
advances. Indian biotechnology companies along with others globally will have
to implement the changes as the rule takes effectJune
4, 2012.

The rule is in response to President Obama’s
Executive Order 13563 which called for improving regulation and regulatory
review.

Specifically,
the rule revises sterility requirements under Title 21 of the Code of Federal
Regulations (CFR), sub chapter F, parts 600 through 680. It eliminates
specified sterility test methods, culture media formulae or formulation, and
culture media test requirements. It also does away with specified membrane
filtration procedure requirements for certain products. There is no need
for specified sterility test requirements for most bulk material. It
modifies the repeat sterility test requirements, so that repeat tests will
occur only once for each lot.

It
also replaces the storage and maintenance requirements for cultures of test
organisms used to determine the ‘growth-promoting qualities’ of culture media
with validation requirements specifying that any sterility test used is able to
consistently detect the presence of viable contaminating micro-organisms, and
with verification of ‘growth-promoting properties’ or micro-organism-detection
capabilities of test and test components.

In
addition, it also replaces the sample size or amount requirement with a requirement
that the sample be appropriate to the material being tested. It substitutes the
interpretation of test results section under 610.12(c) with a requirement that
manufacturers establish, implement and follow written procedures for sterility
testing that describe, at a minimum, the test method used, the method of
sampling.

It
identifies the Director of Centre for Drug Evaluation and Research (CDER) as
one of the two Centre directors authorized to grant an exemption under the
exception provision at 610.12(h)(2). In the proposed rule, the Centre for
Devices and Radiological Health was erroneously identified in this exception,
instead of the CDER.

It
revises the definition of the term “sterility” under 600.3(q). It eliminates
certain exceptions for allergenic products related to sterility testing under
680.3(c). The proposed rule received several comments from industry and the
final rule includes the agency’s response to those recommendations.

Overall,
FDA recognizes the role innovation plays in bringing safe and effective
products to market in a timely and cost-efficient manner. The agency’s efforts
to review and update biologics regulations, to keep pace with technological
developments helps to boost regulatory science, stated the guidance.

The Indian Heart Watch (IHW)
study has revealed the truth
behind the prevalence, awareness, treatment and control of key risk factors
that are driving the country’s growing cardiovascular disease (CVD)
epidemic, in a first-of-a-kind presentation of data at the World Congress of
Cardiology .

The study assessed the prevalence of
different “lifestyle” and biologicalCVDrisk
factors across the country – and
results show that these risk factors are now at higher levels inIndiathan in developed
countries and regions such as theUSAandWestern
Europe.

Seventy-nine per cent of men and 83 per cent
of women were found to be physically inactive, while 51 per cent of men and 48
per cent of women were found to have high fat diets. Some 60 per cent of men
and 57 per cent of women were found to have a low intake of fruit and
vegetables, while 12 per cent of men and 0.5 per cent of women smoke.

Moreover, the prevalence of biological and
metabolic risk factors was also found to be high. Overweight and obesity was
reported in 41 per cent of men and 45 per cent of women. High blood pressure
was reported in 33 per cent of men and 30 per cent of women, while high
cholesterol was found in one-quarter of all men and women. Diabetes (and or
metabolic syndrome) was also reported in 34 per cent of men and 37 per cent of
women.

“Indiahas the dubious
distinction of being known as the coronary and diabetes capital of the world,”
said Prof. Prakash Deedwania,UniversityofCalifornia,San
Francisco,USA.
“These results show why - and must prompt the government to develop public
health strategies that will change lifestyles, if these risk factors are to be
controlled.”

According to the IHW, urban social development
is also playing a role in the development of CVD risk factors. Risk factors
such as smoking, high fat intake and low fruit/vegetable intake were shown to
be more common in less developed cities, while physical inactivity was seen to
be more prevalent in highly-developed cities. Accordingly, metabolic risk
factors such as obesity, high blood pressure and high cholesterol were seen to
be more prevalent in more highly developed cities.

“These results show that improving urban
planning and overall living conditions are critical to the curb the CVD
epidemic inIndia,”
said Dr. Rajeev Gupta,FortisEscortsHospital,Jaipur,India.
“But, this can not be the extent of government efforts which have to include
improvements in basic amenities, healthcare facilities and, perhaps most
importantly, education that will enable people to take responsibility for their
own actions.”

Indeed, the results of the IHW study showed
that even among literate middle-class urban Indians there is a low awareness
and control rates of these risk factors. Of the approximately one-third of
study participants found to have hypertension, only about half (57 per cent)
were aware of their high blood pressure, only 40 per cent were on treatment and
only 25 per cent had adequate control. This is in contrast to more than 75 per
cent awareness in most high and middle-income countries, where more than 50–60
per cent of people with high blood pressure are controlled.

The study took place over a five-year period
(2006–2010) and involved 6,000 men and women from 11 cities across various
regions of India was conducted under the chairmanship of Professors Prakash
Deedwania (University of California San Francisco, Fresno, USA) and Rajeev
Gupta (Fortis Escorts Hospital, Jaipur, India).